Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Argenx Se ADR (NQ: ARGX )

588.50 -7.08 (-1.19%)
Streaming Delayed Price Updated: 9:35 AM EST, Nov 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Argenx Se ADR

< Previous 1 2 3 4 5 6 7 8 9 Next >
Argenx Q3 Revenue, EPS Beats Excite Bullish Biotech Analysts: 'Most Enviable I&I Pipeline In Entire Industry'
Argenx SE ADR shares jumped after impressive earnings. Analysts raised price targets and noted strong pipeline and global expansion. 
Via Benzinga
This Atlassian Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
Via Benzinga
This Huntington Ingalls Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Via Benzinga
The Latest Analyst Ratings For argenx
Via Benzinga
Biotech Stocks : Are You A Trader Or A Longer Term Investor?
Biotech bull market is intact as indicated by large cap biopharma and the best performing funds. 
Via Talk Markets
Peeling Back The Layers: Exploring argenx Through Analyst Insights
Via Benzinga
What 25 Analyst Ratings Have To Say About argenx
Via Benzinga
The Analyst Verdict: argenx In The Eyes Of 27 Experts
Via Benzinga
Breaking Down argenx: 12 Analysts Share Their Views
Via Benzinga
Argenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune Diseases
Amgen tested its drug, Uplizna, in generalized myasthenia gravis, a market where Argenx's Vyvgart leads. 
Via Investor's Business Daily
Snowflake, Hawaiian Electric Industries And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Johnson & Johnson Seeks FDA Approval For Muscle Weakness Drug And Gears Up Showdown With Argenx and UCB
Johnson & Johnson has submitted a Biologics License Application (BLA) to the FDA for nipocalimab, seeking its first global approval for generalized myasthenia gravis (gMG). This submission follows... 
Via Benzinga
Exposures Product Safety
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
The Analyst Verdict: argenx In The Eyes Of 12 Experts
Via Benzinga
Key Takeaways From argenx Analyst Ratings
Via Benzinga
This CrowdStrike Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Via Benzinga
Northrop Grumman To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
Why Is European Drugmaker Argenx Stock Trading Higher On Monday?
The FDA has approved Argenx's Vyvgart Hytrulo for chronic inflammatory demyelinating polyneuropathy, with projections of $1.2 billion in U.S. revenues by 2030. 
Via Benzinga
Exposures Product Safety
Argenx Surges After Its Bread-And-Butter Drug Wins Another FDA Approval
This is the second approval for the biotech company's drug, Vyvgart Hytrulo. 
Via Investor's Business Daily
Exposures Product Safety
Micron To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
RXO, Alnylam Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
After Biohaven Kerfuffle, Immunovant Dives On A Surprise Delay
Immunovant, which jumped Wednesday on news from rival Biohaven, reversed course Thursday. 
Via Investor's Business Daily
Biohaven Stock Stumbles As Protein-Degrading Drug Falls Short Of Expectations In Early-Stage Study
Biohaven shares drop as interim data from the Phase 1 study of BHV-1300 fell short of investor expectations. 
Via Benzinga
Biohaven Crashes After Protein-Degrading Drug Misses Expectations; Immunovant, Argenx Jump
The company says it's still running additional testing of the drug, calling the results "positive." 
Via Investor's Business Daily
Why AppLovin Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Why Duolingo Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
ARGX Stock Earnings: argenx Misses EPS, Misses Revenue for Q1 2024
ARGX stock results show that argenx missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Exact Sciences Reports Q1 Loss, Joins Beyond Meat, Duolingo And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Cartesian Therapeutics' Rare Disease Candidate Shows Long Lasting Benefit Over Argenx's Vyvgart, Analyst Initiates With Buy
Cartesian Therapeutics' autoimmune disease treatment with re-dosable mRNA CAR-Ts. Learn about Descartes-08, a promising anti-BCMA CAR-T therapy offering deeper, longer-lasting efficacy than current... 
Via Benzinga
Tesla To $120? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.